SoftOx småprat

[XCR]

Tenkte det samme… Game over.

[Olympus]

Håper Almås blir holdt personlig ansvarlig og noen anmelder fyren. Det han har bedrevet er svindel.
Fraråder folk på det sterkeste i å delta videre i selskapet. Det beste er at selskapet går konk og Almås og resten av styret må sone og blir holdt personlig ansvarlig her.

[Andre10k]

Rimelig uinvesterbar denne skrapaktien nå?

[erpe80]

Antal idag 10 342 871
NYA 111,6 millioner

[Sander57]

Dette er vel det største fallet noensinne for en aksje på OBX, fra en toppkurs på 110 til en bunn på 0,40. Her handler det vel ikke bare om et svakt marked, men sannsynligvis like mye om et ditto drevet selskap, slik det antydes her på forumet.

[XCR]

Det verste er vel at toppen og hypen ble generert av falske/dårlig formulerte børsmeldinger. Her ble mange lurt, inkludert meg selv. Dumpet alt ved åpning idag, jeg er ferdig.

[stAMy]

Lurer på hva han duden med 270k + aksjer som lo av alle på fb gruppen nå tenker.

Glad jeg kastet ut på 7kr.

[TekBot]

SOFTX; Update regarding the financial situation in Softox Solutions AS,

Not for release, publication or distribution, in whole or in part directly or indirectly, in Australia, Canada, Japan or the United States (or any other jurisdiction in which the release, publication or distribution would be unlawful). This announcement does not constitute an offer of any of the securities described herein.

Oslo, 27 March 2024: Reference is made to the stock exchange release from Softox Solutions AS (the “Company”) on March 13th 2024 regarding summons for extraordinary general meeting with agenda inter alia contemplated conversion of debt to equity, private placement and repair issue (the “EGM”).
…

Vis børsmeldingen

Private Placement

The Company hereby announces that is has raised NOK 22,330,571 in gross proceeds in the contemplated private placement (“Private Placement”), divided by NOK 14.005.371 by way of conversion of supplier debt and NOK 8.325.200 in cash, through the allocation of 111,652,854 new shares, at a subscription price per share in the Private Placement of NOK 0,2 per share (the Offer Price"). The Offer Price was set through a bookbuilding process conducted by the Company’s manager SpareBank 1 Markets.

The consummation of the Private Placement by the issuance of the new shares will be subject to approval by the EGM, scheduled to be held tomorrow 27 March 2024 at 10 a.m. CET.

Settlement of the new shares in the Private Placement is expected to take place on or about 2nd April 2024, subject to registration of the share capital increase in the Company pertaining to the issuance of the New Shares by the Norwegian Register of Business Enterprises (the “NRBE”), on a delivery-versus-payment (“DVP”) basis.

The new shares are expected to be tradable from on or about 8th April 2024, but not before registration of the share capital increase in the Company pertaining to the issuance of the new shares by the NRBE.

The net cash proceeds from the Private Placement will be used to secure the Company’s data and patent portfolio, as well as funding operations at a minimum level over the next 3-6 months.

The aforementioned result of the Private Placement and Offer Price will result in adjustments being made in the final resolutions to be made by the EGM, inter alia the adjustment of the final number of shares to be issued and the Offer Price.

Debt Conversion

The Company has also agreed with creditors that shall convert their loans of approximately NOK 76.208.596 into new shares in the Company (the “Debt Conversion”) that the conversion shall be based on the same principles as in the Private Placement. Consequently, the subscribers in the Debt Conversion will convert NOK 76.208.596 and be allocated 381,042,981 new shares at a subscription price per share equal to the Offer Price.

The conditions and principles described above for completion and delivery of new shares in the Private Placement also applies for the Debt Conversion.

New share capital

Following registration of the new shares pertaining to the Private Placement and the Debt Conversion, the Company will have a share capital of NOK 10.068.474 divided into 503.423.706 shares, each with a par value of NOK 0.02.

Equal treatment considerations

The Private Placement and the Debt Conversion represents a deviation from the shareholders’ pre-emptive right to subscribe for and be allocated the Offer Shares. The Board has considered the Private Placement and the Debt Conversion in light of the equal treatment obligations under the Norwegian Securities Trading Act and the principles set out in Oslo Børs’ Circular no. 2/2014 and is of the opinion that the waiver of the preferential rights inherent in a private placement is considered necessary in the interest of time and successful completion in order to secure funding of and the viability of the Company. Further, the Private Placement was launched after a market sounding process with a number of investors (including both new investors and existing shareholders) to reduce the transaction risk, and the transaction has been marketed through a process to secure a market-based offer price. In addition, the Private Placement and the Debt Conversion is conditioned upon the EGM resolution at which the Company’s shareholders will be given an opportunity to express their opinion and vote over the related share capital increases. Taking into consideration the time, costs and expected terms of alternative methods of securing the necessary funding, as well as the proposed Subsequent Offering (as described below), the Board has concluded that the completion of the Private Placement and the Debt Conversion, including the waiver of the preferential rights inherent to the Private Placement, is in the common interest of the shareholders of the Company.

Subsequent Offering

Subject to completion of the Private Placement and the Debt Conversion and certain other conditions, the Company will carry out a subsequent offering of up to 125,000,000 new shares which, if applicable and subject to applicable securities laws, will be directed towards existing shareholders in the Company as of as of March 27 2024, as registered in the Company’s shareholder register at Euronext Securities Oslo (VPS) on 3 April 2024, and who (i) were not included in the pre-sounding phase of the Private Placement, (ii) were not allocated offer shares in the Private Placement, and (iii) are not resident in a jurisdiction where such an offer would be illegal or would (in jurisdictions other than Norway) require a prospectus, filing, registration, or similar action (the “Subsequent Offering”). The subscription price in the Subsequent Offering will be equal to the Offer Price.

The Subsequent Offering will be subject to (i) a resolution by the EGM tomorrow 27 March 2024 approving the amended proposal for Subsequent Offering, (ii) the prevailing market price of the Company’s shares and (iii) registration of a national prospectus.

Further information about the Subsequent Offering will be given in a future stock exchange notice. The Board reserves the right not to carry out the Subsequent Offering in the event

that the Company’s shares trade at or below the subscription price in the Subsequent Offering (i.e. the Offer Price) at meaningful volumes.

For any questions or interview requests, please contact:
Geir Almås, Chair of SoftOx Solutions AS
Mail: ir@soft-ox.com
Phone: Geir Almås: (+47) 977 59 071

About SoftOx Solutions AS
SoftOx Solutions AS (SoftOx) is a Medtech and pharmaceutical company listed on Euronext Growth Oslo under ‘SOFTX’. SoftOx Solutions AS was founded in 2012 and is headquartered in Oslo. The SoftOx Solutions Group includes: the holding company SoftOx Solutions AS, the Malmö subsidiary, and subsidiaries SoftOx Defense Solutions AS and SoftOx Disinfection AS. SoftOx is developing a highly effective antimicrobial solution for use in biofilm, viral and antimicrobial resistant infections. The patent-protected technology is based on extensive research and development in partnership with leading Nordic research institutes.

For more information on SoftOx, visit www.soft-ox.com

Kilde

[Sander57]

Det var vel til og med en professor i Danmark som gikk god for produktene, og som hjalp til med haussingen?

[XCR]

Produktene tror jeg fortsatt har ett enormt potensiale. Men Geir Almås skulle vært erstattet for mange år siden.

[stAMy]

Han har mistet all kredibilitet.

[XCR]

Mannen er en svindler, punkt slut.

[XCR]

Jeg har tapt like mye som han, men heldigvis på ett tidligere stadium hvor dette faktisk så lovende ut. Den han har holdt på med den siste tiden på tross av hva alle vi andre har opplevd er jo galskap.

[Hotdog]

Tiltross for emisjon på 20 øre - så omsettes den for ca 45 øre. Enkelte drømmer fremdeles om suksess for aksjen. 🫣

[stAMy]

Helt fair, men du satt ikke og lo av folk som var kritiske. Du har hele tiden skjønt risikoen her. Det tror jeg ikke han har gjort.

[XCR]

Ja det var himmel eller helvette, det var jeg klar over. Men det skulle avgjøres av forskningsresultater, ikke av en tulling ved roret. Det er det som gjør meg forbanna.

[stone]

Første gang jeg så Almås var i et innslag på TV2 under coronaen, og jeg tenkte umiddelbart at det selskapet der skal jeg holde meg langt unna - kun basert på tryne faktor. Etter å ha lest mye positivt om teknologien her inne ombestemte jeg meg og trodde de satt på en skikkelig game changer spesielt ift SIS… Har også tapt en del på denne, til og med 2 ganger… Men har heldigvis kastet kortene for lenge siden… Neste gang skal jeg stole mer på magefølelsen vedrørende ledelse

[Hotdog]

Hvor stor prosentandel av selskapet sitter Almås klanen igjen med etter emisjonen? De er vel nesten de eneste som ikke er vannet ut. Regner med et raskt salg av sårselskapet - et salg som nok har «vært klart» en stund.

[stAMy]

Dette må jo være salg på insideinformasjon? Kan ikke skjønne noe annet?

[Sval_Kapital]

Ligger i -98% på totalt innskudd ca 200k… Klar over risiko, men faen så surt strategien lederne av dette selskapet har kjørt selskapet i grøfta
Kanke annet enn å bære lære av det…